Metabolic and morphological differences between rapidly proliferating cancerous and normal breast epithelial cells

Biotechnology Progress

Volumn 24, Issue 2, 2008, Pages 334-341

  Meadows, Adam L ^a,b   Kong, Becky ^a   Berdichevsky, Marina ^a   Roy, Siddhartha ^a   Rosiva, Rosiva ^a   Blanch, Harvey W ^a   Clark, Douglas S ^a  

^a University of California   (United States)

^b Amyris Biotechnologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL GROWTH; GLUCOSE; GROWTH RATE; METABOLISM; METABOLITES; MORPHOLOGY; NUTRIENTS;

EPITHELIAL CELLS; FINITE LIFESPAN; KEY PATHWAYS; METABOLIC FLUXES;

TUMORS;

CARBON DIOXIDE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; PYRUVIC ACID; TUMOR PROTEIN;

ARTICLE; BIOSYNTHESIS; BREAST; BREAST TUMOR; CELL PROLIFERATION; CULTURE MEDIUM; CYTOLOGY; EPITHELIUM CELL; FEMALE; HUMAN; MASS FRAGMENTOGRAPHY; METABOLISM; PATHOLOGY; PENTOSE PHOSPHATE CYCLE; PHYSIOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

BREAST; BREAST NEOPLASMS; CARBON DIOXIDE; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA; EPITHELIAL CELLS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; HUMANS; NEOPLASM PROTEINS; PENTOSE PHOSPHATE PATHWAY; PYRUVIC ACID;

EID: 42049085016     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp070301d     Document Type: Article

References (44)

1. Warburg, O. Ist die aerobe Glykolyse spezifisch für die Turmoren? Biochem. Zietschrift 1929, 204, 482.
2. Czernin, J.; Phelps, M. E. Positron emission tomography scanning: current and future applications. Annu. Rev. Med. 2002, 53, 89-112.
3. Dang, C. V.; Semenza, G. L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999, 24 (2), 68-72.
4. Gatenby, R. A.; Gawlinski, E. T. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003, 63 (14), 3847-3854.
5. Gatenby, R. A.; Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004, 4 (11), 891-899.
6. Mazurek, S.; Boschek, C.; Eigenbrodt, E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J. Bioenerg. Biomembr. 1997, 29 (4), 315-330.
7. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3 (10), 721-732.
8. Pfeiffer, T.; Schuster, S.; Bonhoeffer, S. Cooperation and competition in the evolution of ATP-producing pathways. Science 2001, 292 (5516), 504-507.
9. Hatzivassiliou, G.; Zhao, F.; Bauer, D. E.; Andreadis, C.; Shaw, A. N.; Dhanak, D.; Hingorani, S. R.; Tuveson, D. A.; Thompson, C. B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8 (4), 311-321.
10. Gatenby, R. A.; Vincent, T. L. An evolutionary model of carcinogenesis: Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Cancer Res. 2003, 63 (19), 6212-6220.
11. Anderson, A. R.; Weaver, A. M.; Cummings, P. T.; Quaranta, V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006, 127 (5), 905-915.
12. Comin-Anduix, B.; Boros, L. G.; Marin, S.; Boren, J.; Callol-Massot, C.; Centelles, J. J.; Torres, J. L.; Agell, N.; Bassilian, S.; Cascante, M. Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells. J. Biol. Chem. 2002, 277 (48), 46408-46414.
13. Forbes, N. S.; Meadows, A. L.; Clark, D. S.; Blanch, H. W. Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. Metab. Eng. 2006, 8 (6), 639-652.
14. Cascante, M.; Centelles, J.; Veech, R.; Lee, W.; Boros, L. Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation. Nutr. Cancer 2000, 36 (2), 150-154.
15. Fantin, V. R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9 (6), 425-434.
16. Stampfer, M. Isolation and Growth of Human Mammary Epithelial Cells. J. Tissue Cult. Methods 1985, 9 (2), 107-115.
17. Brenner, A. J.; Stampfer, M. R.; Aldaz, M. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 1998, 17, 199-205.
18. Meadows, A. L.; Roy, S.; Clark, D. S.; Blanch, H. W. Optimal design of metabolic flux analysis experiments for anchorage-dependent mammalian cells using a cellular automaton model. Biotechnol. Bioeng. 2007, 98 (1), 221-229.
19. Freshney, R. I. Culture of Animal Cells, 3rd ed.; Wiley-Liss: New York 1994; p 486.
20. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
21. Damadian, R. NMR in Medicine; Springer-Verlag: Berlin, 1981.
22. Degani, H.; Dejordy, J.; Salomon, Y. Stimulation of cAMP an phosphomonoester production by melanotropin in melanoma cells: 31P NMR studies. Proc. Natl. Acad. Sci. U.S.A. 1991, 88 (February), 1506-1510.
23. Portais, J.; Schuster, R.; Merle, M.; Canioni, P. Metabolic flux determination in C6 glioma cells using carbon-13 distribution upon [1-C-13]glucose incubation. Eur. J. Biochem. 1993, 217 (1), 457-468.
24. Metz, K. R.; Dunphy, L. K. Absolute quantitation of tissue phospholipids using P-31 NMR spectroscopy. J. Lipid Res. 1996, 37 (10), 2251-2265.
25. Lanks, K. W. End products of glucose and glutamine metabolism by L929 cells. J. Biol. Chem. 1987, 262 (21), 10093-10097.
26. Harrison, A. G. Ion chemistry of protonated glutamic acid derivatives. Int. J Mass Spectrom. 2001, 210 (1-3), 361-370.
27. Hellerstein, M. K.; Neese, R. A. Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations. Am. J. Physiol. 1999, 276 (6 Pt 1), E1146-E1170.
28. Ozturk, S.; Palsson, B. Chemical decomposition of glutamine in cell culture media: effect of media type, pH, and Serum concentration. Biotechnol. Prog. 1990, 6 (March-April), 121-128.
29. 13C-NMR, MS and metabolic flux balancing in biotechnology research. Q. Rev. Biophys. 1998, 31, 41-106.
30. Savinell, J. M.; Palsson, B. O. Network analysis of intermediary metabolism using linear optimization. 1. Development of mathematical formalism. J. Theor. Biol. 1992, 154 (4), 421-454.
31. Glunde, K.; Jie, C.; Bhujwalla, Z. M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004, 64 (12), 4270-4276.
32. Wilkinson, R. The effect of charcoal/dextran treatment on select serum components. Art Sci. Tissue Culture 1993, 12 (3/4), 1-2; 6; 8-10.
33. Katzenellenbogen, B. S.; Frasor, J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin. Oncol. 2004, 31 (1 Suppl 3), 28-38.
34. Strobl, J.; Lippman, M. Prolonged retention of estradiol by human breast cancer cells in tissue culture. Cancer Res. 1979, 39 (September), 3319-3327.
35. Werner, S.; Grose, R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 2003, 83 (3), 835-870.
36. Riedemann, J.; Sohail, M.; Macaulay, V. M. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells. Biochem. Biophys. Res. Commun. 2007, 355 (3), 700-706.
37. Semenza, G. L.; Artemov, D.; Bedi, A.; Bhujwalla, Z.; Chiles, K.; Feldser, D.; Laughner, E.; Ravi, R.; Simons, J.; Taghavi, P.; Zhong, H. 'The metabolism of tumours': 70 years later. Novartis Found. Symp. 2001, 240, 251-260; discussion 260-264.
38. Pedersen, P. L.; Mathupala, S.; Rempel, A.; Geschwind, J. F.; Ko, Y. H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 2002, 1555 (1-3), 14-20.
39. Mazurek, S.; Eigenbrodt, E.; Failing, K.; Steinberg, P. Alterations in the glycolytic and glutaminolytic pathways after malignant transformation of rat liver oval cells. J. Cell. Physiol. 1999, 181 (1), 136-146.
40. Boros, L. G.; Serkova, N. J.; Cascante, M.; Lee, W. Use of metabolic pathway flux information in targeted cancer drug design. Drug Discovery Today: Therapeutic Strategies 2004, 1 (4), 435-443.
41. Thomas, M.; Bader, C.; Monet, J. D. Sex steroid hormone modulation of nadph pathways in Mcf-7 cells. Cancer Res. 1990, 50 (4), 1195-1200.
42. Osborne, C. K.; Bardou, V.; Hopp, T. A.; Chamness, G. C.; Hilsenbeck, S. G.; Fuqua, S. A.; Wong, J.; Allred, D. C.; Clark, G. M.; Schiff, R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 2003, 95 (5), 353-361.
43. Petersen, O. W.; Hoyer, P. E.; van Deurs, B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res. 1987, 47 (21), 5748-5751.
44. Ricketts, D.; Turnbull, L.; Ryall, G.; Bakhshi, R.; Rawson, N. S.; Gazet, J. C.; Nolan, C.; Coombes, R. C. Estrogen and progesterone receptors in the normal female breast. Cancer Res. 1991, 51 (7), 1817-1822.